OneSource Specialty Pharma Ltd

OneSource Speci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

OneSource Specialty Pharma Ltd

₹ 1,274 -4.23%
21 Feb - close price
onesourcecdmo.com BSE: 544292 NSE: ONESOURCE
About

Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]

Key Points

Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.

Website BSE NSE
  • Market Cap ₹ 14,583 Cr.
  • Current Price ₹ 1,274
  • High / Low ₹ 1,800 / 1,255
  • Stock P/E
  • Book Value ₹
  • Dividend Yield 0.00 %
  • ROCE -9.72 %
  • ROE -31.8 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of -44.1% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Miscellaneous Industry: Miscellaneous

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Jun 2024 Sep 2024 Dec 2024
34 56 78 334 393
72 67 73 257 249
Operating Profit -39 -10 5 77 143
OPM % -114% -19% 7% 23% 36%
-32 -74 1 -1 -95
Interest 25 26 20 45 46
Depreciation 18 20 19 68 69
Profit before tax -114 -130 -33 -37 -67
Tax % -0% -0% -0% 12% 4%
-114 -130 -33 -42 -69
EPS in Rs -6.02
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
21 128 39 172
93 132 151 260
Operating Profit -71 -4 -112 -88
OPM % -334% -3% -290% -51%
1 -128 -526 -137
Interest 16 46 48 89
Depreciation 34 53 114 76
Profit before tax -121 -231 -800 -391
Tax % 0% -0% -0% -0%
-121 -231 -800 -391
EPS in Rs
Dividend Payout % -0% -0% -0% -0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 100%
TTM: 344%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 62%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: -44%
Last Year: -32%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Sep 2024
Equity Capital 2 3 4 4
Reserves 774 1,009 781 401
386 1,182 864 612
96 248 365 266
Total Liabilities 1,258 2,442 2,015 1,283
633 1,231 1,361 972
CWIP 431 490 334 43
Investments -0 -0 4 11
195 722 314 257
Total Assets 1,258 2,442 2,015 1,283

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
-118 -416 -163 -107
-207 -692 -68 511
381 1,162 118 -391
Net Cash Flow 56 54 -112 13

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 38 67 36
Inventory Days 87 615
Days Payable 762 420
Cash Conversion Cycle -637 67 232
Working Capital Days -1,085 271 -1,953
ROCE % -3% -12%

Shareholding Pattern

Numbers in percentages

19 Recently
Dec 2024Jan 2025
37.76% 37.76%
17.44% 17.44%
12.56% 12.56%
32.24% 32.24%
No. of Shareholders 98,42598,425

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

Credit ratings

Concalls